Literature DB >> 8425184

Metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene by monomorphic N-acetyltransferase (NAT1) and polymorphic N-acetyltransferase (NAT2) in colon cytosols of Syrian hamsters congenic at the NAT2 locus.

D W Hein1, M A Doll, K Gray, T D Rustan, R J Ferguson.   

Abstract

Acetylator genotype is regulated at the polymorphic acetyltransferase (NAT2) gene locus in humans and other mammals such as Syrian hamsters. Human slow acetylator phenotypes have been associated with increased incidences of urinary bladder cancers, whereas rapid acetylators have been associated with increased incidences of colorectal cancers. The genetic predisposition of rapid acetylators to colorectal cancers suggests localized metabolic activation of arylamine carcinogen metabolites by polymorphic N-acetyltransferase (NAT2) in colon tissues. We tested this hypothesis in Bio. 82.73/H Syrian hamster lines which are congenic at the NAT2 gene locus. Congenic Bio. 82.73/H Syrian hamsters expressed acetylator genotype-dependent N-acetyltransferase activity in colon cytosols toward arylamine carcinogens such as 2-aminofluorene and 4-aminobiphenyl. Partial purification of the hamster colon cytosol by anion exchange chromatography identified two N-acetyltransferase isozymes analogous to those previously described in liver and urinary bladder. One of the isozymes (NAT2) exhibited acetylator genotype-dependent expression for the N-acetylation of each arylamine tested: p-aminophenol; 2-aminofluorene; 4-aminobiphenyl; 3,2'-dimethyl-4-aminobiphenyl; and 2-amino-dipyrido[1,2-a:3',2'd]imidazole as well as for the metabolic activation (via O-acetylation) of N-hydroxy-2-aminofluorene to form DNA adducts. Although NAT2 catalyzed the metabolic activation of N-hydroxy-2-acetyl-aminofluorene to DNA adducts, the rates were lower, were paraoxon-sensitive, and did not reflect acetylator genotype. A second isozyme (NAT1) also catalyzed the N-acetylation of each arylamine as well as the metabolic activation of N-hydroxy-2-aminofluorene and N-hydroxy-2-acetylaminofluorene to DNA adducts at rates that were independent of acetylator genotype. Metabolic activation of N-hydroxy-2-aminofluorene catalyzed by both NAT1 and NAT2 was resistant to 100 microM paraoxon, an inhibitor of microsomal deacetylases. Metabolic activation of N-hydroxy-2-acetylaminofluorene by NAT1 and NAT2 was partially sensitive to 100 microM paraoxon. Michaelis-Menten kinetic constants were determined for the colon NAT1 and NAT2 isozymes and compared to previous determinations for liver NAT1 and NAT2. For each of the arylamines tested, both apparent Km and apparent Vmax were higher for NAT2 than NAT1. In rapid acetylator hamster colon, NAT2/NAT1 activity ratios were 18 and 13 for the N-acetylation of 2-aminofluorene and 4-aminobiphenyl and 28 for the O-acetylation of N-hydroxy-2-aminofluorene. These results strongly support the role of the polymorphic NAT2 gene locus in the local metabolic activation of N-hydroxyarylamine carcinogens in colon and provide mechanistic support for human epidemiological studies suggesting a predisposition of rapid acetylators to colorectal cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8425184

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  N-Acetyltransferase polymorphism and human cancer risk.

Authors:  X Yang; T Takeshita; K Morimoto
Journal:  Environ Health Prev Med       Date:  2000-01       Impact factor: 3.674

2.  Association of genotypes of carcinogen-metabolizing enzymes and smoking status with bladder cancer in a Japanese population.

Authors:  Xiaoyi Cui; Xi Lu; Mizue Hiura; Hisamitsu Omori; Wataru Miyazaki; Takahiko Katoh
Journal:  Environ Health Prev Med       Date:  2012-09-09       Impact factor: 3.674

3.  Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases.

Authors:  D W Hein; T D Rustan; R J Ferguson; M A Doll; K Gray
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

4.  N-Acetyltransferase 2 (NAT2) gene polymorphism and exposure to smoking in lung cancer of Chinese males.

Authors:  Fangshuo Tian; Yue Zhang; Yangwu Ren; Li Shen; Wei Wu; Baosen Zhou
Journal:  Med Oncol       Date:  2014-07-09       Impact factor: 3.064

Review 5.  N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk.

Authors:  D W Hein
Journal:  Oncogene       Date:  2006-03-13       Impact factor: 9.867

6.  Human acetylator genotype: relationship to colorectal cancer incidence and arylamine N-acetyltransferase expression in colon cytosol.

Authors:  J W Rodriguez; W G Kirlin; R J Ferguson; M A Doll; K Gray; T D Rustan; M E Lee; K Kemp; P Urso; D W Hein
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

7.  Smoking and COX-2 functional polymorphisms interact to increase the risk of gastric cardia adenocarcinoma in Chinese population.

Authors:  Xue-Mei Zhang; Rong Zhong; Li Liu; Ying Wang; Ju-Xiang Yuan; Peng Wang; Chuang Sun; Zhi Zhang; Wen-Guang Song; Xiao-Ping Miao
Journal:  PLoS One       Date:  2011-07-14       Impact factor: 3.240

8.  Genetic polymorphism of the N-acetyltransferase 2 gene, and susceptibility to prostate cancer: a pilot study in north Indian population.

Authors:  Daya S L Srivastava; Rama D Mittal
Journal:  BMC Urol       Date:  2005-08-06       Impact factor: 2.264

9.  Association Between NAT2 Polymorphisms and Lung Cancer Susceptibility.

Authors:  Chang Liu; Wei Cui; Lin Cong; Li Wang; Xinjian Ruan; Jia Jia; Yanfang Liu; Xiaoyan Jia; Xia Zhang
Journal:  Medicine (Baltimore)       Date:  2015-12       Impact factor: 1.817

10.  Cloning and characterization of arylamine N-acetyltransferase genes from Mycobacterium smegmatis and Mycobacterium tuberculosis: increased expression results in isoniazid resistance.

Authors:  M Payton; R Auty; R Delgoda; M Everett; E Sim
Journal:  J Bacteriol       Date:  1999-02       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.